Intellia Therapeutics Public Company

Primary contact

Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. Specifically, it is focused on the development of proprietary therapeutics using a biological tool known as the CRISPR/Cas9 system, which has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course.
Primary contact

Funding 💰

Total $85M
Select investors Novartis, OrbiMed, Atlas Venture, Fidelity Management and Research Company, Foresite Capital
Last update: October 8, 2020